Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

(2018) François-Xavier Danlos et al.   EUROPEAN JOURNAL OF CANCER

Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment

(2017) Panagiotis T. Diamantopoulos et al.   JOURNAL OF IMMUNOTHERAPY

New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma

(2017) Juliane Behling et al.   MELANOMA RESEARCH

Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies

(2017) David J. Byun et al.   Nature Reviews Endocrinology

Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review

(2017) Bum Jun Kim et al.   Oncotarget

Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma

(2016) H. Vallet et al.   ANNALS OF ONCOLOGY

Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm

(2016) C.L. Haddox et al.   ANNALS OF ONCOLOGY

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

(2016) A. M. Menzies et al.   ANNALS OF ONCOLOGY

Myasthenic crisis and polymyositis induced by one dose of nivolumab

(2016) Toshihiro Kimura et al.   CANCER SCIENCE

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Case of Nivolumab-Induced Myositis

(2016) E. Fox et al.   ONCOLOGIST

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody

(2016) Mehmet Asim Bilen et al.   Journal for ImmunoTherapy of Cancer

Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis

(2015) Zhiyong Chen et al.   CLINICAL RHEUMATOLOGY

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features

(2015) Aryeh Fischer et al.   EUROPEAN RESPIRATORY JOURNAL

Case of respiratory discomfort due to myositis after administration of nivolumab

(2015) Miri Yoshioka et al.   JOURNAL OF DERMATOLOGY

Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy

(2015) Mizuki Nishino et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug-Associated Dermatomyositis Following Ipilimumab Therapy

(2015) Shirwa Sheik Ali et al.   JAMA Dermatology

Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab

(2014) Gary Hunter et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

(2014) B. Liao et al.   NEURO-ONCOLOGY

The Multicenter Study of a New Assay for Simultaneous Detection of Multiple Anti-Aminoacyl-tRNA Synthetases in Myositis and Interstitial Pneumonia

(2014) Ran Nakashima et al.   PLoS One

Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins

(2011) Manabu Fujimoto et al.   ARTHRITIS AND RHEUMATISM

Pathophysiology of inflammatory and autoimmune myopathies

(2011) Marinos C. Dalakas   PRESSE MEDICALE

Paraneoplastic myopathy

(2009) Katalin Dankó et al.   CURRENT OPINION IN RHEUMATOLOGY